tonapofylline
Small moleculeexperimental
Clinical trial activity
3 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
1
Phase 4
0
Earliest trial started Jul 1, 2008 (NCT00709865)
Timeline
Indications
Mechanism of action
- Adenosine A1 receptorANTAGONIST
ADORA1 antagonist
Chemistry & pharmacology
Loading structure…
SMILES
CCCn1c(=O)c2[nH]c(C34CCC(CCC(=O)O)(CC3)CC4)nc2n(CCC)c1=O- Mol. weight
- 416.52 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL414157 ↗
Also known as
- 3-(4-(2,6-dioxo-1,3-dipropyl-2,3,6,7-tetrahydro-1h-purin-8-yl)-bicyclo(2.2.2)oct-1-yl)propionic acid
- bg9928
- bg9928
- bg9928
- bg 9928
- bg-9928
- bg-9928
- bg-9928
- bio4683
- bio 4683
- bio-4683
- bio5770
- bio 5770
- bio-5770
- bio7505
- bio 7505
- bio-7505
- bio8170
- bio 8170
- bio-8170
- bio9002
- bio 9002
- bio-9002
- tonapofylline
- tonapofylline
- tonapofylline
- tonapofylline
- tonapofylline
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00858156 | Phase 1 | Apr 1, 2009 | Biogen |
| NCT00745316 | Phase 2 | Feb 1, 2009 | Biogen |
| NCT00709865 | Phase 2/Phase 3 (Phase 3) | Jul 1, 2008 | Biogen |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Biogen | For profit | 3 | 3 | 3 | 2008 |
1 organizations
Page 1 / 1